Related Experiment Video
Updated: Apr 7, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Pathophysiology and a Rational Basis of Therapy
Jordi Gracia-Sancho1, Raquel Maeso-Díaz, Jaime Bosch
1Barcelona Hepatic Hemodynamic Laboratory, IDIBAPS, Hospital Clinic de Barcelona, CIBEREHD, Barcelona, Spain.
Portal hypertension, a complication of chronic liver disease, stems from liver damage and increased vascular tone. Therapies target liver injury, fibrosis, vascular tone, and blood flow for improved patient outcomes.
Area of Science:
- Hepatology and Gastroenterology
- Cardiovascular Physiology
- Liver Disease Pathophysiology
Background:
- Portal hypertension is a major complication of chronic liver disease, leading to severe outcomes like variceal bleeding, ascites, and renal dysfunction.
- It arises from increased resistance to portal blood flow due to structural liver abnormalities and heightened hepatic vascular tone.
- Hepatic endothelial dysfunction, characterized by altered nitric oxide (NO) production and increased vasoconstrictors, plays a crucial early role.
Purpose of the Study:
- To elucidate the complex pathophysiological mechanisms underlying portal hypertension in chronic liver disease.
- To review current and emerging therapeutic strategies targeting the distinct abnormalities contributing to portal hypertension.
- To highlight the potential for combination therapies to more effectively manage portal hypertension.
Main Methods:
- Review of existing literature on the pathophysiology of portal hypertension.
- Analysis of mechanisms including vascular architecture distortion, endothelial dysfunction, and splanchnic vasodilation.
- Evaluation of therapeutic approaches targeting etiological factors, fibrogenesis, vascular tone, and blood flow.
Main Results:
- Portal hypertension is driven by structural liver changes and endothelial dysfunction, leading to increased hepatic vascular resistance and splanchnic vasodilation.
- Therapeutic strategies include etiological treatments, antifibrotic agents, drugs enhancing NO availability (like statins), and agents reducing splanchnic blood flow.
- Combination therapy shows promise for more effective portal pressure reduction compared to single-agent treatments.
Conclusions:
- Effective management of portal hypertension requires addressing multiple pathophysiological pathways simultaneously.
- Future treatments will likely involve etiological therapies combined with antifibrotic and endothelial function-improving drugs in early cirrhosis.
- Nonselective beta-blockers remain important for advanced stages, but combination approaches offer a more comprehensive strategy.
Related Concept Videos
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Rational Emotive Behavior Therapy
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drug Therapy
Antianxiety Medications
Psychotherapy